Haoxi Health Technology Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of December 2025 for Haoxi Health Technology Ltd, a foreign private issuer. The report details the closing of a private placement offering that occurred on December 3, 2025, following a Securities Purchase Agreement signed on November 26, 2025.
Key Financial Metrics
- Gross Proceeds: $5 million raised from the private placement.
- Use of Proceeds: Working capital and general corporate purposes.
- Capital Raised Structure: Issuance of 6,250,000 Class A ordinary shares and 12,500,000 warrants.
- Warrant Terms: Initial exercise price of $0.80 per share with a floor price of $0.20. Warrants expire five years from the Initial Exercise Date.
- Debt and Liquidity: The filing text does not provide specific values for existing debt, cash flow, or liquidity ratios outside of the new capital raised.
Material Changes
The primary material change is the increase in equity capital and the potential dilution from the issuance of shares and warrants. The filing does not provide comparative financial data (e.g., revenue or profit changes) against prior periods as this is a transaction-specific report rather than a periodic financial statement.
Outlook, Risks, and Unusual Items
- Warrant Reset Mechanism: On the 7th calendar day after issuance, the warrant exercise price will reset to 22% of the "Minimum Price" (defined by Nasdaq Listing Rule 5635(d)), with a corresponding adjustment to the number of warrant shares.
- Exchange Option: Starting 21 days after the Initial Exercise Date, holders may exchange warrants for 0.9 times the underlying warrant shares.
- Regulatory Compliance: The offering was conducted under Regulation S, with purchasers representing they are non-U.S. persons.
- Risks: Potential dilution to existing shareholders due to the warrant reset mechanism and the large number of warrants issued relative to the shares sold.
Investor Verification Checklist
- Verify the current trading price of Class A ordinary shares to calculate the post-reset warrant exercise price.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and conditions.
- Assess the impact of the 12.5 million warrants on total share count and potential dilution.
- Confirm the company's current cash position to understand the immediate liquidity impact of the $5 million gross proceeds.